Ignite Creation Date:
2024-05-06 @ 7:53 PM
Last Modification Date:
2024-10-26 @ 3:16 PM
Study NCT ID:
NCT06179069
Status:
RECRUITING
Last Update Posted:
2024-05-17
First Post:
2023-12-07
Brief Title:
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
Sponsor:
Zai Lab Shanghai Co Ltd
Organization:
Zai Lab Hong Kong Ltd
Study Overview
Official Title:
An Open-label Multicenter Study of ZL-1310 to Evaluate the Safety Tolerability and Pharmacokinetics in Subjects With Small Cell Lung Cancer
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
An Open-label Multicenter Study of ZL-1310 as a Single Agent and In Combination with Atezolizumab to Evaluate the Safety Tolerability and Pharmacokinetics in Subjects with Small Cell Lung Cancer
Detailed Description:
This is an open-label ascending multiple-dose phase 1 study evaluating ZL-1310 as a single agent and in combination with Atezolizumab in subjects withmetastatic or extensive-stage SCLC who have progressed after at least one platinum-based chemotherapy regimen
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None